MolMed: AIFA approva commercializzazione Zalmoxis. Titolo vola in Borsa - Economia e Finanza - Repubblica.it
MolMed now part of AGC Biologics | LinkedIn
European Population Genetic Substructure: Further Definition of Ancestry Informative Markers for Distinguishing among Diverse European Ethnic Groups | Molecular Medicine | Full Text
Molmed, la giapponese Agc supera il 50% in Opa - Il Sole 24 ORE
Frontiers | Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs
Azioni MolMed: Quotazione, Andamento e Previsioni | Emanuele Perini
Will MolMed soon have its first Cell therapy on the Market?
Antioxidants | Free Full-Text | Cellular Aging Characteristics and Their Association with Age-Related Disorders
Molmed, l'Opa giapponese in bilico per golden power - ilGiornale.it
MolMed - Wikipedia
Molmed, Opa dei giapponesi di Agc. Per Berlusconi 30 milioni di plusvalenza - Affaritaliani.it
MolMed - YouTube
MolMed, viaggio nell'officina dei superfarmaci per le terapie geniche - Il Sole 24 ORE
Innovazione, la Borsa corre con plastica e super batteri - Corriere.it
Relazione sulla Remunerazione MolMed S.p.A.
European Population Genetic Substructure: Further Definition of Ancestry Informative Markers for Distinguishing among Diverse European Ethnic Groups | Molecular Medicine | Full Text
Aptamer-Based Antibacterial and Antiviral Therapy against Infectious Diseases | Journal of Medicinal Chemistry
Overview of the Italian Primary Markets
Voluntary Tender Offer launched by AGC Inc. on all ordinary shares of MolMed: the Board of Directors approves the Issuer's not
Press release issued by MolMed S.p.A. at the request of AGC Inc. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PA
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHER
Ultime Notizie Molmed News
I giapponesi di Agc l'anciano un'Opa su Molmed e il titolo corre in borsa
